Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.

被引：17
|
作者：
O'Hara, Mark H.
O'Reilly, Eileen Mary
Wolff, Robert A.
Wainberg, Zev A.
Ko, Andrew H.
Rahma, Osama E.
Fisher, George A.
Lyman, Jaclyn Paige
Cabanski, Christopher R.
Karakunnel, Joyson Joseph
Gherardini, Pier Federico
Kitch, Lacey J.
Bucktrout, Samantha
Christopher, Elizabeth
Mick, Rosemarie
Chen, Richard
Trifan, Ovidiu C.
Salvador, Lisa
O'Donnell-Tormey, Jill
Vonderheide, Robert H.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4019
引用
收藏
页数：3
相关论文
共 29 条
  • [1] A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients
    O'Hara, Mark H.
    O'Reilly, Eileen M.
    Rosemarie, Mick
    Varadhachary, Gauri
    Wainberg, Zev A.
    Ko, Andrew
    Fisher, George A.
    Rahma, Osama
    Lyman, Jaclyn P.
    Cabanski, Christopher R.
    Carpenter, Erica L.
    Hollmann, Travis
    Gherardini, Pier Federico
    Kitch, Lacey
    Selinsky, Cheryl
    LaVallee, Theresa
    Trifan, Ovid C.
    Dugan, Ute
    Hubbard-Lucey, Vanessa M.
    Vonderheide, Robert H.
    CANCER RESEARCH, 2019, 79 (13)
  • [2] A phase 1b/2 study of CD40 agonistic monoclonal antibody (APX005M) together with gemcitabine and nab-paclitaxel with or without nivolumab in untreated metastatic pancreatic adenocarcinoma patients
    O'Hara, Mark
    Mick, Rosemarie
    Lyman, Jaclyn
    Xu, Jingying
    Hosseini, Maryam
    LaVallee, Theresa
    Gherardini, Pier Federico
    Vance, Barbara
    Trifan, Ovid
    Dugan, Ute
    Shalabi, Aiman
    Ibrahim, Ramy
    Vonderheide, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [3] APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma
    Reni, Michele
    LANCET ONCOLOGY, 2021, 22 (01): : 10 - 11
  • [4] CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
    O'Hara, Mark H.
    O'Reilly, Eileen M.
    Varadhachary, Gauri
    Wolff, Robert A.
    Wainberg, Zev A.
    Ko, Andrew H.
    Fisher, George
    Rahma, Osama
    Lyman, Jaclyn P.
    Cabanski, Christopher R.
    Mick, Rosemarie
    Gherardini, Pier Federico
    Kitch, Lacey J.
    Xu, Jingying
    Samuel, Theresa
    Karakunnel, Joyson
    Fairchild, Justin
    Bucktrout, Samantha
    LaVallee, Theresa M.
    Selinsky, Cheryl
    Till, Jacob E.
    Carpenter, Erica L.
    Alanio, Cecile
    Byrne, Katelyn T.
    Chen, Richard O.
    Trifan, Ovid C.
    Dugan, Ute
    Horak, Christine
    Hubbard-Lucey, Vanessa M.
    Wherry, E. John
    Ibrahim, Ramy
    Vonderheide, Robert H.
    LANCET ONCOLOGY, 2021, 22 (01): : 118 - 131
  • [5] PHASE II OF CD40 AGONISTIC ANTIBODY SOTIGALIMAB (APX005M) IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH METASTATIC MELANOMA WITH CONFIRMED DISEASE PROGRESSION ON ANTI-PD-1 THERAPY
    Weiss, Sarah
    Sznol, Mario
    Shaheen, Montaser
    Berciano-Guerrero, Miguel-Angel
    Felip, Enriqueta
    Rodriguez-Abreu, Delvys
    Arance, Ana Maria
    Boni, Valentina
    Linette, Gerald
    Schuchter, Lynn
    Gonzalez-Cao, Maria
    Iannotti, Nicholas
    Ganti, Apar Kishor
    Hauke, Ralph
    Berrocal, Alfonso
    Filbert, Erin
    Kluger, Harriet
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A422 - A422
  • [6] Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)
    Kluger, Harriet
    Weiss, Sarah A.
    Olszanski, Anthony J.
    Schuchter, Lynn
    Linette, Gerald P.
    Garland, Linda
    Iannotti, Nicholas O.
    Johnson, Melissa
    Avsar, Emin
    Srivastava, Minu K.
    Trifan, Ovid C.
    Edelman, Martin J.
    CANCER RESEARCH, 2019, 79 (13)
  • [7] A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
    Weiss, Sarah A.
    Sznol, Mario
    Shaheen, Montaser
    Berciano-Guerrero, Miguel-Angel
    Couselo, Eva Munoz
    Rodriguez-Abreu, Delvys
    Boni, Valentina
    Schuchter, Lynn M.
    Gonzalez-Cao, Maria
    Arance, Ana
    Wei, Wei
    Ganti, Apar Kishor
    Hauke, Ralph J.
    Berrocal, Alfonso
    Iannotti, Nicholas O.
    Hsu, Frank J.
    Kluger, Harriet M.
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 74 - 81
  • [8] Phase I/II safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab in metastatic melanoma patients
    Johnson, Daniel Johnson H.
    Lecagoonporn, Srisuda
    Bernatchez, Chantale
    Haymaker, Cara
    Bentebibel, Salah
    Uemura, Marc
    Yee, Cassian
    Amaria, Rodabe
    Patel, Sapna
    Tawbi, Hussein
    Glitza, Isabella
    Davies, Michael A.
    Wong, Michael K.
    Hwu, Wen-Jen
    Hwu, Patrick
    Overwijk, Willem
    Diab, Adi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [9] Napabucasin plus nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study
    Bekaii-Saab, T.
    Okusaka, T.
    Goldstein, D.
    Oh, D-Y.
    Ueno, M.
    Ioka, T.
    Fang, W.
    Anderson, E. C.
    Noel, M. S.
    Reni, M.
    Choi, H. J.
    Goldberg, J.
    Oh, S. C.
    Li, C-P.
    Tabernero, J.
    Li, J.
    Foos, E.
    Oh, C.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1084 - S1085
  • [10] A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)
    Bekaii-Saab, T.
    Starodub, A.
    El-Rayes, B.
    O'Neil, B.
    Shahda, S.
    Ciombor, K.
    Noonan, A.
    Hanna, W.
    Sehdev, A.
    Shaib, W.
    Mikhail, S.
    Neki, A.
    Oh, C.
    Li, Y. Z.
    Li, W.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
123